---
schema_version: "secwatch.filing_event.v1"
accession: "0001842952-23-000040"
form_type: "8-K"
ticker: "CNTX"
cik: "0001842952"
company_name: "Context Therapeutics Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:40:18.245302+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Context Therapeutics discontinues ONA-XR, prioritizes CTIM-76; 2022 net loss $14.8M

## Summary
- Discontinued ONA-XR due to elevated LFTs in 3 patients and competitive landscape; exploring strategic options.
- Focusing on CTIM-76 (CLDN6 x CD3 bispecific) for solid tumors; IND expected Q1 2024.
- Cash $35.5M at Dec 31, 2022, down from $49.7M; cash runway extended into late 2024.
- 2022 net loss $14.8M vs $10.5M in 2021; R&D $7.1M, G&A $7.8M.
- CTIM-76 preclinical data at AACR April 17, 2023; investor R&D webinar same day.

## SEC filing metadata
- accession: 0001842952-23-000040
- form_type: 8-K
- ticker: CNTX
- cik: 0001842952
- company_name: Context Therapeutics Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842952/000184295223000040/0001842952-23-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842952/000184295223000040/cntx-20230317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001842952-23-000040
- JSON: https://secwatch.observer/filing/0001842952-23-000040.json
- Plain text: https://secwatch.observer/filing/0001842952-23-000040.txt

## Key facts
- Earnings Releases
  Context Therapeutics Inc. reported the year ended December 31, 2022 results: net income $14.8 million.
  - Period: the year ended December 31, 2022
  - Net income: $14.8 million
  - Result: reported results
  source text: Context reported a net loss of $14.8 million for 2022, as compared to $10.5 million for the same period in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842952/000184295223000040/0001842952-23-000040-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.